2 completed, 1 unknown. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Unknown 1 |
| Phase 2 | 3 | Completed 2, Unknown 1 |
Follow BNT162b2: new trials by email Literature Review of BNT162b2 trials Research Report on BNT162b2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine BNT162b2, mRNA-1273, MVC-COV1901 - COVID-19, Breakthrough Infection | Phase 1 / Phase 2 | Unknown | Chang Gung Memorial Hospital | 340 | 2021-11-30 | 2022-07-25 |
| Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines Ad26.COV2.S, BNT162b2, mRNA-1273 - COVID-19 | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 867 | 2021-05-28 | 2025-04-20 |
| A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults BNT162a1, BNT162b1, BNT162b2 - Infections, Respiratory, Virus Diseases | Phase 1 / Phase 2 | Completed | BioNTech SE | 512 | 2020-04-23 | 2024-07-12 |
COVID-19 (3) · Breakthrough Infections (1) · RNA Virus Infections (1) · Respiratory Tract Infections (1) · Severe Acute Respiratory Syndrome (1) · Virus Diseases (1)
BioNTech SE (1) · Chang Gung Memorial Hospital (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
Germany (1) · Taiwan (1) · United States (1)
Cheng-Hsun Chiu, MD, PhD (1) · Kirsten E Lyke, M.D. (1) · Robert L Atmar, M.D. (1)
PMID 35081293, PMID 35798000, PMID 36125366, PMID 36399969, PMID 37433788, PMID 37992183, PMID 39197299, PMID 40298376
5UM1AI148684-02 (1)